Page last updated: 2024-12-06

n-methylscopolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-Methylscopolamine: A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71183
CHEMBL ID376897
CHEMBL ID3140030
CHEBI ID135361
SCHEMBL ID65398
MeSH IDM0029432

Synonyms (45)

Synonym
n-methyl scopolamine
gtpl316
[3h]n-methylscopolamine
gtpl317
[3h]nms
(1r,2r,4s,5s)-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium
[3h]n-methyl scopolamine
PDSP2_000640
3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 7-[(2s)-3-hydroxy-1-oxo-2-phenylpropoxy]-9,9-dimethyl-, (1a,2b,4b,5a,7b)
hsdb 5420
n-methylscopolamine
13265-10-6
methscopolamine ,
CHEBI:135361
methyl scopolamine
7-(3-hydroxy-2-phenyl-propionyloxy)-9,9-dimethyl-3-oxa-9-azonia-tricyclo[3.3.1.0*2,4*]nonane
bdbm50241132
methylscopolamine
(-)-n-methylscopolamine
methscopolamine cation
CHEMBL376897 ,
n-methylhyoscine
methscopolamine ion
3-oxa-9-azoniatricyclo(3.3.1.0(2,4))nonane, 7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9,9-dimethyl-, (7(s)-(1alpha,2beta,4beta,5alpha,7beta))-
vdr09vtq8u ,
metylskopolamin
unii-vdr09vtq8u
methscopolamine [vandf]
methylscopolamine [who-dd]
3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 7-((2s)-3-hydroxy-1-oxo-2-phenylpropoxy)-9,9-dimethyl-, (1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.)-
3-oxa-9-azoniatricyclo(3.3.1.02,4)nonane, 7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9,9-dimethyl-, (7(s)-(1.alpha.,2.beta.,4.beta.,5.alpha.,7.beta.))-
SCHEMBL65398
DTXSID0046931 ,
3c0 ,
W-108020
CHEMBL3140030 ,
AB00385828_19
n-methylscopolamine (nms)
bdbm214800
DB11315
(1r,2r,4s,5s,7s)-7-{[(2s)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0~2,4~]nonane
Q27087955
[(1s,2s,4r,5r)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2s)-3-hydroxy-2-phenylpropanoate
bdbm50538323
PD062645

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The neurotoxicity induced by carbamazepine may be involved in the teratogenic and adverse effects of overdose associated with the treatment of manic-depressive illness and seizures."( Carbamazepine-induced neurotoxicity and its prevention by NMDA in cultured cerebellar granule cells.
Chuang, DM; Gao, XM, 1992
)
0.28
" Thus, pirenzepine provides good results in double-contrast studies (equal to SMB), while presenting no adverse effects."( Usefulness and safety of pirenzepine in double-contrast study of upper gastrointestinal tract: comparison with scopolamine methylbromide.
Bartolozzi, C; Boraschi, P; Braccini, G; Falaschi, F; Marraccini, P; Marrucci, A; Testa, R,
)
0.13

Pharmacokinetics

ExcerptReferenceRelevance
"In rats the pharmacokinetic interactions between the anticholinergic drug biperiden and [3H]quinuclidinyl benzylate ([3H]QNB) or [3H]N-methylscopolamine ([3H]NMS) is affected by the sequence in which the drugs are administered."( Effect of sequence of administration on the pharmacokinetic interaction between the anticholinergic drug biperiden and [3H]quinuclidinyl benzylate or [3H]N-methylscopolamine in rats.
Ichimura, F; Ishizaki, J; Nakashima, E; Ohshima, T; Takayasu, T; Yokogawa, K, 1998
)
0.7
" Pharmacokinetic parameters were estimated from measurements of the concentration of imidafenacin in serum, the bladder, and the submaxillary gland by liquid chromatography-mass spectrometry/mass spectrometry."( Selective binding of bladder muscarinic receptors in relation to the pharmacokinetics of a novel antimuscarinic agent, imidafenacin, to treat overactive bladder.
Fukata, A; Ito, Y; Nakamura, M; Ogoda, M; Seki, M; Yamada, S, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" Furthermore, the compounds are tertiary amines, implying some advantages in terms of bioavailability pertinent to future in vivo pharmacological studies."( Carbamoylcholine homologs: novel and potent agonists at neuronal nicotinic acetylcholine receptors.
Bräuner-Osborne, H; Falch, E; Frølund, B; Jensen, AA; Krogsgaard-Larsen, P; Mikkelsen, I, 2003
)
0.32

Dosage Studied

ExcerptRelevanceReference
"01-1 mg/kg) increased the number of penile erections with bell-shaped dose-response curves."( Septohippocampal cholinergic pathway and penile erections induced by dopaminergic and cholinergic stimulants.
Maeda, N; Matsuoka, N; Yamaguchi, I, 1990
)
0.28
" However, the dose-response for Aech-M was biphasic such that at high concentrations (greater than 50 microM) there was a reduction in its ability to attenuate cAMP formation."( Effect of acetylethylcholine mustard on muscarinic receptor-coupled attenuation of cAMP formation in intact GH3 cells.
Baker, SP; Bolden, CP, 1990
)
0.28
" Assuming that the binding of carbachol to one site (Site 1) increases [14C]aminopyrine accumulation but its binding to the other site (Site 2) reduces [14C]aminopyrine accumulation, we analysed the dose-response curves for the carbachol effects in the absence and presence of different concentrations of atropine, pirenzepine and AF-DX 116."( Carbachol-induced potentiation and inhibition of acid secretion by guinea pig gastric gland.
Haga, T; Honda, N; Ichiyama, A; Kajimura, M; Kaneko, E, 1990
)
0.28
" 4-DAMP (10(-9) to 10(-6) M) caused a progressive parallel rightward shift in the acetylcholine dose-response curve without a change in maximal amylase release."( Muscarinic receptor subtypes on rat pancreatic acini: secretion and binding studies.
Louie, DS; Owyang, C, 1986
)
0.27
" Acini preexposed to concentrations of carbamylcholine of 10(-6) M or greater showed shifts to the right in the subsequent carbamylcholine dose-response curves of amylase release."( Short-term cholinergic desensitization of rat pancreatic secretory response.
Asselin, J; Larose, L; Morisset, J, 1987
)
0.27
" Biphasic dose-response curves to cholecystokinin for amylase release shifted to the right with an increase in the concentration of the drug."( CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini.
Iwamoto, Y; Kuzuya, T; Yamamoto, R, 1987
)
0.27
"day-1 for 14 days, resulted in a shift to the left in the amylase dose-response curve to carbamylcholine (Cch) and an increase in receptor concentration compared to saline-infused group."( Contraindication for osmotic mini-pump in the abdominal cavity to study muscarinic cholinergic control of pancreatic enzyme secretion and muscarinic receptors.
Larose, L; Loiselle, J; Morisset, J, 1986
)
0.27
" Intrapericardial propranolol or atenolol (50 micrograms/kg) had the same effect on isoprenaline heart rate dose-response curves and on the sympathetic component of the arterial baroreceptor-heart rate reflex as did conventional, 5-fold greater, intravenous doses of the drugs."( Selective manipulation of neurohumoral control of the cardiac pacemaker by drugs given intrapericardially.
Lew, MJ; Ludbrook, J; Pavia, JM; Quail, AW; Rutter, PC, 1987
)
0.27
" Gallamine caused parallel shifts to the right in the dose-response curves for inhibition of adenylate cyclase activity by the highly efficacious muscarinic agonist oxotremorine-M and the partial agonist Bm 5 [N-methyl-N-(1-methyl-4-pyrrolidino)-2-butynyl acetamide]."( Gallamine allosterically antagonizes muscarinic receptor-mediated inhibition of adenylate cyclase activity in the rat myocardium.
Ehlert, FJ, 1988
)
0.27
"In dispersed acini from guinea pig pancreas, replacing extracellular sodium by tetraethylammonium (1) abolished carbamylcholine-stimulated amylase secretion but did not alter the increase in amylase secretion caused by the C-terminal octapeptide of cholecystokinin, bombesin, ionophore A23187, vasoactive intestinal peptide or 8-bromoadenosine 3':5' monophosphate, (2) caused a parallel rightward shift in the dose-response curve for carbamylcholine-stimulated amylase secretion and (3) inhibited binding of N-[3H]methyl scopolamine to muscarinic cholinergic receptors."( The actions of tetraethylammonium on dispersed acini from guinea pig pancreas.
Gardner, JD; Jensen, RT; McArthur, KE, 1983
)
0.27
" Binding analysis of carbachol on the muscarinic receptors in terms of two classes of binding sites indicated that the shift in the dose-response curve of amylase secretion was accompanied by modifications to the high and low affinity forms."( Modulation of rat pancreatic amylase secretion and muscarinic receptor populations by chronic bethanechol treatment.
Blanchard, L; Dumont, Y; Fregeau, C; Larose, L; Morisset, J; Poirier, GG, 1983
)
0.27
" It is concluded that the effects of estrogens on the endocrine system in peri- and postmenopausal women are influenced by chemical structure, dosage and mode of administration of the estrogen as well as by the endogenous hormone profile."( Treatment with oral estrone sulphate in the female climacteric. II. Hormonal aspects.
Carlström, K; Lagrelius, A; Lunell, NO, 1981
)
0.26
" The equilibrium dose-response curve for carbachol is shifted to the right, suggesting competitive blockade."( A photoisomerizable muscarinic antagonist. Studies of binding and of conductance relaxations in frog heart.
Birdsall, NJ; Erlanger, BF; Lester, HA; Nargeot, J; Stockton, J; Wassermann, NH, 1982
)
0.26
" Ten of the studies are dose-response evaluations."( Sleep spindles: pharmacological effects in humans.
Hirshkowitz, M; Karacan, I; Thornby, JI, 1982
)
0.26
" Reduction in mAChR number after PBCM treatment was determined by Scatchard analysis of specific [3H]-NMS binding sites and compared with the expected reduction (q values) calculated from dose-response curves for carbachol-stimulated IP3 formation before and after PBCM treatment."( Relationship between muscarinic receptor occupancy and response in rat parotid acinar cells.
Baum, BJ; Dai, Y, 1993
)
0.29
" A muscarinic agonist, carbachol, produced a dose-related rightward shift of the dose-response curve to IMI."( Suppression of the rat micturition reflex by imipramine.
Kim, CY; Sohn, UD, 1997
)
0.3
" Because of the limited brain ChE inhibition obtained following lactation, pups were exposed to CPS directly by gavage, using 3 dosing regimens to yield a dose response."( Changes in rat brain cholinesterase activity and muscarinic receptor density during and after repeated oral exposure to chlorpyrifos in early postnatal development.
Carr, RL; Chambers, JE; Tang, J, 1999
)
0.3
" We have evaluated the consequences of HFD on heart rate (HR) and blood pressure (BP) circadian cycles and methylscopolamine dose-response curves."( Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension.
Berlan, M; Galitzky, J; Merial, C; Montastruc, JL; Pelat, M; Senard, JM; Verwaerde, P, 1999
)
0.3
" These data indicate that some of the pronounced neurobehavioral changes observed following fenamiphos dosing may be centrally mediated (blocked by SCO only), despite the small amount of inhibition of brain ChE."( Differential profiles of cholinesterase inhibition and neurobehavioral effects in rats exposed to fenamiphos or profenofos.
McDaniel, KL; Moser, VC,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (11)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.33500.00001.23267.7930AID142418; AID1482301; AID1482310; AID1482311
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.00120.00000.690210.0000AID1185256; AID1185257; AID1185258; AID1185259; AID1185260; AID1482282; AID1482283; AID1648529; AID1648530; AID1648531; AID1648532; AID280352; AID445078; AID668956
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)0.00230.00001.15467.5858AID142556
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.00010.00000.79519.1201AID280354; AID445080; AID668958
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Ki1,995,259,940,700,160.00000.00011.48339.1400AID141739
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.00230.00010.99178.0000AID142562
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.00040.00000.72926.9183AID1185261; AID280355; AID445081; AID668959
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)Ki6,309,570,024,570,880.00000.00010.58908.2600AID140936
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)0.00180.00001.403910.0000AID142290
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.00020.00000.59729.1201AID280351; AID280353; AID445077; AID668955; AID714454; AID714458
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)0.00110.00011.01049.9280AID142434
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.00010.00000.54057.7600AID280353; AID445079; AID668957
Muscarinic acetylcholine receptorCavia porcellus (domestic guinea pig)Ki3,154,785,012,285,440.00000.00010.61203.8019AID140936; AID445079
Muscarinic acetylcholine receptor Cavia porcellus (domestic guinea pig)Ki0.00010.00010.00010.0001AID445080
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)Kd0.00050.00050.16230.9300AID280357
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)EC50 (µMol)0.00010.00000.764610.0000AID359832; AID359833
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)Kd0.00060.00040.41169.1000AID1802458; AID1802459
Muscarinic acetylcholine receptor Cavia porcellus (domestic guinea pig)Kd0.00650.00650.00650.0065AID445084
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
POU domain, class 2, transcription factor 1Homo sapiens (human)Km23.40002.10005.39008.6000AID1769498
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
positive regulation of miRNA transcriptionPOU domain, class 2, transcription factor 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIPOU domain, class 2, transcription factor 1Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPOU domain, class 2, transcription factor 1Homo sapiens (human)
DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
protein bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
sequence-specific DNA bindingPOU domain, class 2, transcription factor 1Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
nucleusPOU domain, class 2, transcription factor 1Homo sapiens (human)
nucleoplasmPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulumPOU domain, class 2, transcription factor 1Homo sapiens (human)
intracellular membrane-bounded organellePOU domain, class 2, transcription factor 1Homo sapiens (human)
chromatinPOU domain, class 2, transcription factor 1Homo sapiens (human)
RNA polymerase II transcription regulator complexPOU domain, class 2, transcription factor 1Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (128)

Assay IDTitleYearJournalArticle
AID140936Binding affinity to Muscarinic acetylcholine receptor M2 by measuring its ability to displace [3H]N-methylscopolamine binding in rat heart1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID280353Binding affinity to human cloned muscarinic receptor M3 expressed in CHO cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID280359Antagonist activity at putative muscarinic receptor M4 assessed as contraction of electrically-stimulated guinea pig lung strips2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID672635Inhibition of Atropa belladonna recombinant hycosamine 6beta-hydroxylase expressed in Escherichia coli using hyoscyamine as substrate assessed as inhibition of hydroxylated product formation at 0.1 mM after 1 hr by HPLC analysis2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Functional characterization of recombinant hyoscyamine 6β-hydroxylase from Atropa belladonna.
AID359836Enhancement of disulfide bond cross-linking formation in rat M3'(3C)-Xa receptor A91C/T549C mutant expressed in african green monkey COS7 cells at 100 nM by Western blotting in presence of urea2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID142556Compound was evaluated for its binding affinity at human muscarinic receptor m4 by the displacement of [3H]NMS radioligand using membranes from transfected chinese hamster ovarian cell1998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Identification and characterization of m4 selective muscarinic antagonists.
AID280352Binding affinity to human cloned muscarinic receptor M2 expressed in CHO cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID1482283Displacement of [3H]UR-AP060 from human muscarinic acetylcholine receptor M2 expressed in CHOK9 cell homogenate after 3 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID142562Compound was evaluated for its binding affinity at human muscarinic receptor m5 by the displacement of [3H]-NMS radioligand using membranes from transfected chinese hamster ovarian cell1998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Identification and characterization of m4 selective muscarinic antagonists.
AID359837Enhancement of disulfide bond cross-linking formation in rat M3'(3C)-Xa receptor F92C/F550C mutant expressed in african green monkey COS7 cells at 100 nM by Western blotting in presence of urea2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID142434Compound was evaluated for its binding affinity at human muscarinic receptor m3 by the displacement of [3H]NMS radioligand using membranes from transfected chinese hamster ovarian cell1998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Identification and characterization of m4 selective muscarinic antagonists.
AID445082Antagonist activity at muscarinic M1 receptor in New Zealand rabbit vas deferens assessed as effect on electrically-stimulated muscle contraction after 60 mins2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID280357Antagonist activity at muscarinic receptor M2 assessed as contraction of electrically-stimulated guinea pig left atria2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID1482311Competitive binding affinity to human muscarinic acetylcholine receptor M2 expressed in CHOK9 cells assessed as W84 pIC50 at 0.1 nM after 2 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID445080Displacement of [3H]NMS from human cloned muscarinic M4 receptor expressed in CHO cells by scintillation counting2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID359831Stimulation of disulfide bond cross-linking formation in rat M3'(3C)-Xa receptor F92C/F550C mutant expressed in african green monkey COS7 cells by scanning densitometry relative to control2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID1185261Displacement of [3H]-NMS from wild-type human muscarinic M5 receptor expressed in CHO-K1 cells by liquid scintillation counting2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
AID280355Binding affinity to human cloned muscarinic receptor M5 expressed in CHO cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID127476Binding affinity against human monoclonal antibody (mAb) 2E2 relative to cocaine by ELISA method.2004Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
Three-dimensional quantitative structure-activity relationship modeling of cocaine binding by a novel human monoclonal antibody.
AID714454Competitive inhibition of EGFP-fused human M1 receptor N-terminal truncated at 17 residues expressed in HEK293 cells after 4 hrs by FRET assay in presence of para-LRB-AC422012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.
AID1185256Displacement of [3H]-NMS from wild-type human muscarinic M2 receptor expressed in Flp-In-CHO cells by liquid scintillation counting2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
AID359840Inverse agonist activity at rat M3'(3C)-Xa receptor expressed in african green monkey COS7 cells assessed as reduction in basal inositol monophosphate accumulation at 10 uM2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID141739Binding affinity to Muscarinic acetylcholine receptor M3 by measuring its ability to displace [3H]N-methylscopolamine binding in rat submandibulary gland1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Synthesis and pharmacological characterization of O-alkynyloximes of tropinone and N-methylpiperidinone as muscarinic agonists.
AID668956Displacement of [3H]N-methylscopolamine from human muscarinic M2 receptor expressed in CHO cells after 120 mins by scintillation counting2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
1,4-dioxane, a suitable scaffold for the development of novel M₃ muscarinic receptor antagonists.
AID280351Binding affinity to human cloned muscarinic receptor M1 expressed in CHO cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID445085Antagonist activity at muscarinic M3 receptor in guinea pig ileum assessed as effect on isotonic tension after 60 mins2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID445083Antagonist activity at muscarinic M2 receptor in guinea pig left atrium assessed as effect on electrically-stimulated inotropic activity after 60 mins2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID445081Displacement of [3H]NMS from human cloned muscarinic M5 receptor expressed in CHO cells by scintillation counting2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID359833Stimulation of disulfide bond cross-linking formation in rat M3'(3C)-Xa receptor F92C/F550C mutant expressed in african green monkey COS7 cells by scanning densitometry2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID1482282Displacement of [3H]UNSW-MK259 from human muscarinic acetylcholine receptor M2 expressed in CHOK9 cells after 3 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID359830Stimulation of disulfide bond cross-linking formation in rat M3'(3C)-Xa receptor A91C/T549C mutant expressed in african green monkey COS7 cells by scanning densitometry relative to control2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID445079Displacement of [3H]NMS from human cloned muscarinic M3 receptor expressed in CHO cells by scintillation counting2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID359839Inverse agonist activity at rat M3'(3C)-Xa receptor F92C/F550C mutant expressed in african green monkey COS7 cells assessed as reduction in basal inositol monophosphate accumulation at 10 uM2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID280358Antagonist activity at muscarinic receptor M3 assessed as contraction of guinea pig ileum2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID672634Activity at Atropa belladonna recombinant hycosamine 6beta-hydroxylase expressed in Escherichia coli assessed as hydroxylated product formation at 0.2 mM after 1 hr by ESI-MS analysis2012Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14
Functional characterization of recombinant hyoscyamine 6β-hydroxylase from Atropa belladonna.
AID142290Compound was evaluated for its binding affinity at human muscarinic receptor m1 by displacement of [3H]-NMS radioligand using membranes in transfected chinese hamster ovarian cell1998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Identification and characterization of m4 selective muscarinic antagonists.
AID714458Displacement of [3H]NMS from EGFP-fused human M1 receptor N-terminal truncated at 17 residues expressed in HEK293 cells after 22 hrs by liquid scintillation counting2012Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5
Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors.
AID1185258Displacement of [3H]-NMS from human muscarinic M2 Y177Q mutant expressed in Flp-In-CHO cells by liquid scintillation counting2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
AID668957Displacement of [3H]N-methylscopolamine from human muscarinic M3 receptor expressed in CHO cells after 120 mins by scintillation counting2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
1,4-dioxane, a suitable scaffold for the development of novel M₃ muscarinic receptor antagonists.
AID1185260Displacement of [3H]-NMS from human muscarinic M2 W422A mutant expressed in Flp-In-CHO cells by liquid scintillation counting2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID1482301Competitive binding affinity to human muscarinic acetylcholine receptor M2 expressed in CHOK9 cells assessed as W84 pIC50 at 2 nM after 2 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID359835Enhancement of disulfide bond cross-linking formation in rat M3'(3C)-Xa receptor F92C/F550C mutant expressed in african green monkey COS7 cells at 100 nM by Western blotting2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID668959Displacement of [3H]N-methylscopolamine from human muscarinic M5 receptor expressed in CHO cells after 120 mins by scintillation counting2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
1,4-dioxane, a suitable scaffold for the development of novel M₃ muscarinic receptor antagonists.
AID445077Displacement of [3H]NMS from human cloned muscarinic M1 receptor expressed in CHO cells by scintillation counting2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID1185257Displacement of [3H]-NMS from human muscarinic M2 Y104A mutant expressed in Flp-In-CHO cells by liquid scintillation counting2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
AID280354Binding affinity to human cloned muscarinic receptor M4 expressed in CHO cells2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID359838Inverse agonist activity at rat M3'(3C)-Xa receptor A91C/T549C mutant expressed in african green monkey COS7 cells assessed as reduction in basal inositol monophosphate accumulation at 10 uM2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID445078Displacement of [3H]NMS from human cloned muscarinic M2 receptor expressed in CHO cells by scintillation counting2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID1185259Displacement of [3H]-NMS from human muscarinic M2 Y177Q/T423H mutant expressed in Flp-In-CHO cells by liquid scintillation counting2014Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15
Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity.
AID1482310Competitive binding affinity to human muscarinic acetylcholine receptor M2 expressed in CHOK9 cells assessed as W84 pIC50 at 0.2 nM after 2 hrs by liquid scintillation counting assay2017Journal of medicinal chemistry, 04-27, Volume: 60, Issue:8
Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M
AID280356Antagonist activity at putative muscarinic receptor M1 assessed as contraction of electrically-stimulated rabbit vas deferens2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Synthesis, affinity profile, and functional activity of muscarinic antagonists with a 1-methyl-2-(2,2-alkylaryl-1,3-oxathiolan-5-yl)pyrrolidine structure.
AID142418Compound was evaluated for its binding affinity at human muscarinic receptor m2 by displacement of [3H]NMS radioligand using membranes from transfected chinese hamster ovarian cell1998Bioorganic & medicinal chemistry letters, Aug-04, Volume: 8, Issue:15
Identification and characterization of m4 selective muscarinic antagonists.
AID445084Antagonist activity at muscarinic M4 receptor in guinea pig lung strips assessed as effect on isotonic contraction after 60 mins2010Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1
Synthesis, affinity profile and functional activity of potent chiral muscarinic antagonists with a pyrrolidinylfuran structure.
AID668958Displacement of [3H]N-methylscopolamine from human muscarinic M4 receptor expressed in CHO cells after 120 mins by scintillation counting2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
1,4-dioxane, a suitable scaffold for the development of novel M₃ muscarinic receptor antagonists.
AID359832Stimulation of disulfide bond cross-linking formation in rat M3'(3C)-Xa receptor A91C/T549C mutant expressed in african green monkey COS7 cells by scanning densitometry2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID668955Displacement of [3H]N-methylscopolamine from human muscarinic M1 receptor expressed in CHO cells after 120 mins by scintillation counting2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
1,4-dioxane, a suitable scaffold for the development of novel M₃ muscarinic receptor antagonists.
AID359834Enhancement of disulfide bond cross-linking formation in rat M3'(3C)-Xa receptor A91C/T549C mutant expressed in african green monkey COS7 cells at 100 nM by Western blotting2007The Journal of biological chemistry, Sep-07, Volume: 282, Issue:36
Distinct structural changes in a G protein-coupled receptor caused by different classes of agonist ligands.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))2001The Journal of pharmacology and experimental therapeutics, May, Volume: 297, Issue:2
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1995Molecular pharmacology, Aug, Volume: 48, Issue:2
Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))2006Biotechnology letters, Jan, Volume: 28, Issue:2
High level stable expression of pharmacologically active human M1-M5 muscarinic receptor subtypes in mammalian cells.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))2001Brain research, Oct-05, Volume: 915, Issue:1
Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))2001The Journal of pharmacology and experimental therapeutics, May, Volume: 297, Issue:2
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1995Molecular pharmacology, Aug, Volume: 48, Issue:2
Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
AID1345189Rat M1 receptor (Acetylcholine receptors (muscarinic))1993The Journal of pharmacology and experimental therapeutics, Jul, Volume: 266, Issue:1
Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1994FEBS letters, Sep-19, Volume: 352, Issue:1
A toxin from the green mamba Dendroaspis angusticeps: amino acid sequence and selectivity for muscarinic m4 receptors.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))2006Biotechnology letters, Jan, Volume: 28, Issue:2
High level stable expression of pharmacologically active human M1-M5 muscarinic receptor subtypes in mammalian cells.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1995Molecular pharmacology, Aug, Volume: 48, Issue:2
Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1995Molecular pharmacology, Aug, Volume: 48, Issue:2
Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))2006Molecular pharmacology, Aug, Volume: 70, Issue:2
Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))1998British journal of pharmacology, Nov, Volume: 125, Issue:5
Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
AID1345364Rat M2 receptor (Acetylcholine receptors (muscarinic))1988The EMBO journal, Oct, Volume: 7, Issue:10
Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))2006Biotechnology letters, Jan, Volume: 28, Issue:2
High level stable expression of pharmacologically active human M1-M5 muscarinic receptor subtypes in mammalian cells.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))2006Molecular pharmacology, Aug, Volume: 70, Issue:2
Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))2006Biotechnology letters, Jan, Volume: 28, Issue:2
High level stable expression of pharmacologically active human M1-M5 muscarinic receptor subtypes in mammalian cells.
AID1345189Rat M1 receptor (Acetylcholine receptors (muscarinic))2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))1993The Journal of pharmacology and experimental therapeutics, Jul, Volume: 266, Issue:1
Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists.
AID1345699Rat M3 receptor (Acetylcholine receptors (muscarinic))1993The Journal of pharmacology and experimental therapeutics, Jul, Volume: 266, Issue:1
Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))1994FEBS letters, Sep-19, Volume: 352, Issue:1
A toxin from the green mamba Dendroaspis angusticeps: amino acid sequence and selectivity for muscarinic m4 receptors.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))2001Brain research, Oct-05, Volume: 915, Issue:1
Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1998British journal of pharmacology, Nov, Volume: 125, Issue:5
Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1997Molecular pharmacology, Jul, Volume: 52, Issue:1
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))2001The Journal of pharmacology and experimental therapeutics, May, Volume: 297, Issue:2
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1994FEBS letters, Sep-19, Volume: 352, Issue:1
A toxin from the green mamba Dendroaspis angusticeps: amino acid sequence and selectivity for muscarinic m4 receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1993The Journal of pharmacology and experimental therapeutics, Jul, Volume: 266, Issue:1
Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1994FEBS letters, Sep-19, Volume: 352, Issue:1
A toxin from the green mamba Dendroaspis angusticeps: amino acid sequence and selectivity for muscarinic m4 receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1994FEBS letters, Sep-19, Volume: 352, Issue:1
A toxin from the green mamba Dendroaspis angusticeps: amino acid sequence and selectivity for muscarinic m4 receptors.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1998British journal of pharmacology, Nov, Volume: 125, Issue:5
Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1998British journal of pharmacology, Nov, Volume: 125, Issue:5
Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))2001The Journal of pharmacology and experimental therapeutics, May, Volume: 297, Issue:2
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1998British journal of pharmacology, Nov, Volume: 125, Issue:5
Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1998Molecular pharmacology, Jun, Volume: 53, Issue:6
On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1993The Journal of pharmacology and experimental therapeutics, Jul, Volume: 266, Issue:1
Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))2001AAPS pharmSci, , Volume: 3, Issue:4
Receptor binding studies of soft anticholinergic agents.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1999The Journal of pharmacology and experimental therapeutics, Jan, Volume: 288, Issue:1
Selectivity profile of muscarinic toxin 3 in functional assays of cloned and native receptors.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))2001The Journal of pharmacology and experimental therapeutics, May, Volume: 297, Issue:2
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))2006Biotechnology letters, Jan, Volume: 28, Issue:2
High level stable expression of pharmacologically active human M1-M5 muscarinic receptor subtypes in mammalian cells.
AID1345699Rat M3 receptor (Acetylcholine receptors (muscarinic))2002The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1
Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist.
AID1864502Inhibition of human OCT3 mediated (S,S)-Ethambutol uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864504Inhibition of human OCT3 mediated N-Ethyllidocaine uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1769501Ratio of drug uptake in human OCT1 expressing HEK293 cells at 2.5 uM to drug uptake in empty vector transfected human HEK293 cells at 2.5 uM2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1864499Substrate activity at human OCT2 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1648529Displacement of 4-(2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)amino)hexyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimethyl-3H-i2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M
AID1648531Displacement of 4-(2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-yl)propanamido)ethyl)-amino)hexyl)-5-sulfoindolin-2-ylidene)penta-1,3-d2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M
AID1864503Inhibition of human OCT3 mediated Famotidine uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864508Substrate uptake at human OCT3 overexpressed in HEK293 cells incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1769498Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Km incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1648530Displacement of 4-(2-((1E,3E)-5-((E)-3,3-Dimethyl-1-(6-oxo-6-((2-(4-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)piperazin-1-yl)ethyl)amino)hexyl)-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-3,3-dimet2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M
AID1864498Substrate activity at human OCT3 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1769500Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring intrinsic clearance incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1864501Inhibition of human OCT3 mediated ASP+ uptake overexpressed in HEK293 cells at 20 uM incubated for 5 mins by HPLC-MS/MS analysis relative to control2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864500Substrate activity at human OCT1 overexpressed in HEK293 cells at 2.5 uM incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1864509Substrate uptake in empty vector transfected (OCT3 null) HEK293 cells incubated for 2 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18
Substrates and Inhibitors of the Organic Cation Transporter 3 and Comparison with OCT1 and OCT2.
AID1648532Displacement of 4-(2-((1E,3E)-5-((E)-1-(6-((3,5-Bis((2-(3-(1-(4-(1-(2-oxo-2-(11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)ethyl)piperidin-4-yl)butyl)-1H-imidazol-4-yl)propanamido)ethyl)carbamoyl)benzyl)amino)-6-oxohexyl)-3,3-dimethyl-5-sulfoindo2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Red-Emitting Dibenzodiazepinone Derivatives as Fluorescent Dualsteric Probes for the Muscarinic Acetylcholine M
AID1769499Substrate activity at human OCT1 expressed in HEK293 cells assessed as increase in compound uptake by measuring Vmax incubated for 2 mins by LC-MS/MS analysis2021Journal of medicinal chemistry, 03-11, Volume: 64, Issue:5
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1802458[3H]NMS/Carbachol Binding Assay from Article 10.1074/jbc.M113.503714: \\Novel structural and functional insights into M3 muscarinic receptor dimer/oligomer formation.\\2013The Journal of biological chemistry, Nov-29, Volume: 288, Issue:48
Novel structural and functional insights into M3 muscarinic receptor dimer/oligomer formation.
AID1802459[35S]GTPγS Binding/Immunoprecipitation Assay from Article 10.1074/jbc.M113.503714: \\Novel structural and functional insights into M3 muscarinic receptor dimer/oligomer formation.\\2013The Journal of biological chemistry, Nov-29, Volume: 288, Issue:48
Novel structural and functional insights into M3 muscarinic receptor dimer/oligomer formation.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))2006Molecular pharmacology, May, Volume: 69, Issue:5
Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))2006British journal of pharmacology, Aug, Volume: 148, Issue:7
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (990)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990337 (34.04)18.7374
1990's427 (43.13)18.2507
2000's163 (16.46)29.6817
2010's58 (5.86)24.3611
2020's5 (0.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.52 (24.57)
Research Supply Index6.95 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index51.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (1.17%)5.53%
Reviews7 (0.68%)6.00%
Case Studies2 (0.19%)4.05%
Observational0 (0.00%)0.25%
Other1,005 (97.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]